Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

A functional polymorphism in the CYR61 (IGFBP10) gene is associated with prostate cancer risk

Prostate Cancer and Prostatic Diseases volume 16, pages 95–100 (2013)Cite this article

Subjects

Abstract

BACKGROUND:

CYR61 (cysteine-rich protein 61, also named IGFBP10) is a secreted signaling molecule that promotes angiogenesis and tumor growth. The goal of this study is to determine whether a functional polymorphism in the promoter region of the CYR61 gene (rs3753793) is associated with prostate cancer (PCa) risk and gene expression in Chinese patients.

METHODS:

A total of 665 patients diagnosed with PCa and 703 cancer-free controls were genotyped in this hospital-based case–control study, and 26 PCa tissue samples were evaluated for mRNA expression of CYR61 by real-time quantitative reverse-transcription PCR.

RESULTS:

Men carrying the G allele of rs3753793 (TG+GG) had significantly lower risk of PCa when compared with the TT genotype (odds ratio (OR)=0.76, 95% confidence interval (CI)=0.61–0.95). The association was generally more pronounced among subgroups of PCa patients with advanced stage (OR=0.70, 95% CI=0.53–0.94), Gleason score >7 (OR=0.63, 95% CI=0.46–0.86) and PSA>20 ng ml−1 (OR=0.68, 95% CI=0.53–0.88). Prostate tumors derived from cases with the GT/GG genotypes had significantly lower levels of CYR61 mRNA when compared with cases with the TT genotypes (P=0.02).

CONCLUSIONS:

Our results indicate that the genetic variation of rs3753793 in the CYR61 promoter may contribute to genetic predisposition to PCa and intra-tumor expression gene expression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E . Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277–300.

    Article  PubMed  Google Scholar 

  2. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J et al. Human prostate cancer risk factors. Cancer 2004; 101 (10 Suppl): 2371–2490.

    Article  CAS  PubMed  Google Scholar 

  3. Quinn M, Babb P . Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002; 90: 162–173.

    Article  CAS  PubMed  Google Scholar 

  4. Yang L, Parkin DM, Ferlay J, Li L, Chen Y . Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005; 14: 243–250.

    Article  PubMed  Google Scholar 

  5. Bork P . The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993; 327: 125–130.

    Article  CAS  PubMed  Google Scholar 

  6. Jay P, Berge-Lefranc JL, Marsollier C, Mejean C, Taviaux S, Berta P . The human growth factor-inducible immediate early gene, CYR61, maps to chromosome 1p. Oncogene 1997; 14: 1753–1757.

    Article  CAS  PubMed  Google Scholar 

  7. Perbal B . NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 2001; 54: 57–79.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Bleau AM, Planque N, Perbal B . CCN proteins and cancer: two to tango. Front Biosci 2005; 10: 998–1009.

    Article  CAS  PubMed  Google Scholar 

  9. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP . Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001; 61: 8917–8923.

    CAS  PubMed  Google Scholar 

  10. Xie D, Yin D, Tong X, O'Kelly J, Mori A, Miller C et al. Cyr61 is overexpressed in gliomas and involved in integrin-linked kinase-mediated Akt and beta-catenin-TCF/Lef signaling pathways. Cancer Res 2004; 64: 1987–1996.

    Article  CAS  PubMed  Google Scholar 

  11. Sun ZJ, Wang Y, Cai Z, Chen PP, Tong XJ, Xie D . Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells. Br J Cancer 2008; 99: 1656–1667.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Bouchard L, Tchernof A, Deshaies Y, Lebel S, Hould FS, Marceau P et al. CYR61 polymorphisms are associated with plasma HDL-cholesterol levels in obese individuals. Clin Genet 2007; 72: 224–229.

    Article  CAS  PubMed  Google Scholar 

  13. Livak KJ, Schmittgen TD . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402–408.

    Article  CAS  PubMed  Google Scholar 

  14. Franzen CA, Chen CC, Todorovic V, Juric V, Monzon RI, Lau LF . Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis. Mol Cancer Res 2009; 7: 1045–1055.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF . CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998; 95: 6355–6360.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mo FE, Muntean AG, Chen CC, Stolz DB, Watkins SC, Lau LF . CYR61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol 2002; 22: 8709–8720.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Mo FE, Lau LF . The matricellular protein CCN1 is essential for cardiac development. Circ Res 2006; 99: 961–969.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kireeva ML, Lam SC, Lau LF . Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphavbeta3. J Biol Chem 1998; 273: 3090–3096.

    Article  CAS  PubMed  Google Scholar 

  19. Babic AM, Chen CC, Lau LF . Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 1999; 19: 2958–2966.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Xie D, Miller CW, O'Kelly J, Nakachi K, Sakashita A, Said JW et al. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 2001; 276: 14187–14194.

    Article  CAS  PubMed  Google Scholar 

  21. Menendez JA, Mehmi I, Griggs DW, Lupu R . The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer 2003; 10: 141–152.

    Article  CAS  PubMed  Google Scholar 

  22. Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem 2004; 279: 24015–24023.

    Article  CAS  PubMed  Google Scholar 

  23. Menendez JA, Vellon L, Mehmi I, Teng PK, Griggs DW, Lupu R . A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Oncogene 2005; 24: 761–779.

    Article  CAS  PubMed  Google Scholar 

  24. Sakamoto S, Yokoyama M, Aoki M, Suzuki K, Kakehi Y, Saito Y . Induction and function of CYR61 (CCN1) in prostatic stromal and epithelial cells: CYR61 is required for prostatic cell proliferation. Prostate 2004; 61: 305–317.

    Article  CAS  PubMed  Google Scholar 

  25. Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G et al. Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr Cancer Drug Targets 2009; 9: 791–800.

    Article  CAS  PubMed  Google Scholar 

  26. Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A et al. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer 2009; 125: 2004–2013.

    Article  CAS  PubMed  Google Scholar 

  27. Han JS, Macarak E, Rosenbloom J, Chung KC, Chaqour B . Regulation of Cyr61/CCN1 gene expression through RhoA GTPase and p38MAPK signaling pathways. Eur J Biochem 2003; 270: 3408–3421.

    Article  CAS  PubMed  Google Scholar 

  28. D’Antonio KB, Schultz L, Albadine R, Mondul AM, Platz EA, Netto GJ et al. Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment. Clin Cancer Res 2010; 16: 5908–5913.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the Program for Development of Innovative Research Team in the First Affiliated Hospital of Nanjing Medical University, Provincial Initiative Program for Excellency Disciplines of Jiangsu Province, by the National Natural Science Foundation of China (grant number 81171963 and 81102089) and the Natural Science Foundation of Jiangsu Province (grant number BK2008473 and BK2011773).

Author information

Author notes

  1. L Tao, J Chen and H Zhou: These authors contributed equally to this paper.

Authors and Affiliations

  1. Department of Urology, State Key Laboratory of Reproductive Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

    L Tao, J Chen, H Zhou, C Qin, P Li, Q Cao, J Li, X Ju, C Zhu, P Shao & C Yin

  2. Department of Molecular and Genetic Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China

    M Wang & Z Zhang

Authors
  1. L Tao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Q Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. X Ju
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Z Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. P Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. C Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to P Shao or C Yin.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tao, L., Chen, J., Zhou, H. et al. A functional polymorphism in the CYR61 (IGFBP10) gene is associated with prostate cancer risk. Prostate Cancer Prostatic Dis 16, 95–100 (2013). https://doi.org/10.1038/pcan.2012.41

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2012.41

Keywords

This article is cited by

Search

Advanced search

Quick links